101 related articles for article (PubMed ID: 32004770)
1. Synthetic NRG-1 functionalized DNA nanospindels towards HER2/neu targets for in vitro anti-cancer activity assessment against breast cancer MCF-7 cells.
Baig MMFA; Lai WF; Mikrani R; Jabeen M; Naveed M; Abbas M; Farooq MA; Ahsan A; Kassim SA; Khan GJ; Ansari MT
J Pharm Biomed Anal; 2020 Apr; 182():113133. PubMed ID: 32004770
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of Ligand Functionalized ErbB-3 Targeted Novel DNA Nano-Threads Loaded with the Low Dose of Doxorubicin for Efficient In Vitro Evaluation of the Resistant Anti-Cancer Activity.
Baig MMFA; Lai WF; Ahsan A; Jabeen M; Farooq MA; Mikrani R; Abbas M; Naveed M; Kassim SA; Raza F; Dar AA; Ansari MT
Pharm Res; 2020 Mar; 37(4):75. PubMed ID: 32232574
[TBL] [Abstract][Full Text] [Related]
3. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.
Liu S; Song XL; Wang YH; Wang XM; Xiao Y; Wang X; Cheng L; Li XT
J Drug Target; 2017 Jul; 25(6):541-553. PubMed ID: 28277825
[TBL] [Abstract][Full Text] [Related]
5. Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer.
Abazari R; Mahjoub AR; Ataei F; Morsali A; Carpenter-Warren CL; Mehdizadeh K; Slawin AMZ
Inorg Chem; 2018 Nov; 57(21):13364-13379. PubMed ID: 30351060
[TBL] [Abstract][Full Text] [Related]
6. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle.
Zhang C; Han M; Zhang F; Yang X; Du J; Zhang H; Li W; Chen S
Int J Nanomedicine; 2020; 15():885-900. PubMed ID: 32103944
[TBL] [Abstract][Full Text] [Related]
8. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies.
Lin YL; Tsai NM; Chen CH; Liu YK; Lee CJ; Chan YL; Wang YS; Chang YC; Lin CH; Huang TH; Wang CC; Chi KH; Liao KW
J Nanobiotechnology; 2019 Feb; 17(1):25. PubMed ID: 30728015
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization, and biological verification of anti-HER2 indocyanine green-doxorubicin-loaded polyethyleneimine-coated perfluorocarbon double nanoemulsions for targeted photochemotherapy of breast cancer cells.
Lee YH; Ma YT
J Nanobiotechnology; 2017 May; 15(1):41. PubMed ID: 28521752
[TBL] [Abstract][Full Text] [Related]
10. Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.
Sempkowski M; Zhu C; Menzenski MZ; Kevrekidis IG; Bruchertseifer F; Morgenstern A; Sofou S
Langmuir; 2016 Aug; 32(33):8329-38. PubMed ID: 27468779
[TBL] [Abstract][Full Text] [Related]
11. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
Simeone AM; Broemeling LD; Rosenblum J; Tari AM
Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987
[TBL] [Abstract][Full Text] [Related]
12. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells.
Tari AM; Lim SJ; Hung MC; Esteva FJ; Lopez-Berestein G
Oncogene; 2002 Aug; 21(34):5224-32. PubMed ID: 12149644
[TBL] [Abstract][Full Text] [Related]
13. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
14. The integrin facilitated internalization of fibronectin-functionalized camptothecin-loaded DNA-nanofibers for high-efficiency anticancer effects.
Baig MMFA; Lai WF; Ashraf S; Saleem A; Akhtar MF; Mikrani R; Naveed M; Siddique F; Taleb A; Mudassir J; Khan GJ; Ansari MT
Drug Deliv Transl Res; 2020 Oct; 10(5):1381-1392. PubMed ID: 32661832
[TBL] [Abstract][Full Text] [Related]
15. HER2 Targeted Breast Cancer Therapy with Switchable "Off/On" Multifunctional "Smart" Magnetic Polymer Core-Shell Nanocomposites.
Vivek R; Thangam R; Kumar SR; Rejeeth C; Kumar GS; Sivasubramanian S; Vincent S; Gopi D; Kannan S
ACS Appl Mater Interfaces; 2016 Jan; 8(3):2262-79. PubMed ID: 26771508
[TBL] [Abstract][Full Text] [Related]
16. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
Fan YX; Luo RC; Fang YX; Yan X; Lu CW
Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
[TBL] [Abstract][Full Text] [Related]
17. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand.
Oh B; Park S; Pak JH; Kim I
Biochem Biophys Res Commun; 2012 May; 422(1):42-7. PubMed ID: 22554523
[TBL] [Abstract][Full Text] [Related]
19. Simple synthesis of biocompatible biotinylated porous hexagonal ZnO nanodisc for targeted doxorubicin delivery against breast cancer cell: In vitro and in vivo cytotoxic potential.
Patra P; Mitra S; Das Gupta A; Pradhan S; Bhattacharya S; Ahir M; Mukherjee S; Sarkar S; Roy S; Chattopadhyay S; Adhikary A; Goswami A; Chattopadhyay D
Colloids Surf B Biointerfaces; 2015 Sep; 133():88-98. PubMed ID: 26093304
[TBL] [Abstract][Full Text] [Related]
20. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]